Maarten J Postma

Summary

Affiliation: University of Groningen
Country: The Netherlands

Publications

  1. doi request reprint The dynamic field of pharmacoeconomics
    Maarten Jacobus Postma
    Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, The Netherlands
    Expert Rev Clin Pharmacol 2:125-7. 2009
  2. pmc Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories
    Joel K Kelso
    School of Computer Science and Software Engineering, University of Western Australia, Perth, Western Australia, Australia
    BMC Public Health 13:211. 2013
  3. pmc Contributing factors to influenza vaccine uptake in general hospitals: an explorative management questionnaire study from the Netherlands
    Josien Riphagen-Dalhuisen
    Department of Pharmacy, Division of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Antonius Deusinglaan 1, Groningen, The Netherlands
    BMC Public Health 12:1101. 2012
  4. pmc An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model"
    Hong Anh T Tu
    Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada
    BMC Infect Dis 13:54. 2013
  5. doi request reprint Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples
    Maarten J Postma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 12:555-65. 2013
  6. doi request reprint Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    J Med Econ 15:878-86. 2012
  7. pmc Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands
    Jorien G J Pierik
    Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713 AV, The Netherlands
    BMC Infect Dis 12:110. 2012
  8. ncbi request reprint Dynamic modeling for pandemic influenza
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Expert Rev Vaccines 11:543-6. 2012
  9. pmc Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study
    Harald E Vonkeman
    Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente and University of Twente, Enschede, The Netherlands
    Arthritis Res Ther 10:R144. 2008
  10. ncbi request reprint Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Transfus Med 15:379-87. 2005

Detail Information

Publications122 found, 100 shown here

  1. doi request reprint The dynamic field of pharmacoeconomics
    Maarten Jacobus Postma
    Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, The Netherlands
    Expert Rev Clin Pharmacol 2:125-7. 2009
    ..Here, Professor Postma speaks to Expert Review of Clinical Pharmacology about the dynamic field of pharmacoeconomics. ..
  2. pmc Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories
    Joel K Kelso
    School of Computer Science and Software Engineering, University of Western Australia, Perth, Western Australia, Australia
    BMC Public Health 13:211. 2013
    ..This study estimates the effectiveness and total cost (from a societal perspective, with a lifespan time horizon) of a comprehensive range of social distancing and antiviral drug strategies, under a range of pandemic severity categories...
  3. pmc Contributing factors to influenza vaccine uptake in general hospitals: an explorative management questionnaire study from the Netherlands
    Josien Riphagen-Dalhuisen
    Department of Pharmacy, Division of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Antonius Deusinglaan 1, Groningen, The Netherlands
    BMC Public Health 12:1101. 2012
    ..As there is a lack of research about management factors we assessed factors reported by administrators of general hospitals that are associated with the influenza vaccine uptake among health care workers...
  4. pmc An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model"
    Hong Anh T Tu
    Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada
    BMC Infect Dis 13:54. 2013
    ..To update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011...
  5. doi request reprint Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples
    Maarten J Postma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 12:555-65. 2013
    ..Finally, the need for sometimes complex dynamic models for vaccines is explored, and specific types of models are reviewed, keeping into consideration the adage "complex when needed, straightforward if allowed."..
  6. doi request reprint Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    J Med Econ 15:878-86. 2012
    ....
  7. pmc Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands
    Jorien G J Pierik
    Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713 AV, The Netherlands
    BMC Infect Dis 12:110. 2012
    ..Because the epidemiology of VZV-related diseases in the Netherlands remains largely unknown or incomplete, the main objective of this study was to study the primary care incidence, associated complications and health care resource use...
  8. ncbi request reprint Dynamic modeling for pandemic influenza
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Expert Rev Vaccines 11:543-6. 2012
    ..The future challenge is to couple such complex dynamic models to economic information to inform decision-makers on the relative cost-effectiveness of interventions...
  9. pmc Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study
    Harald E Vonkeman
    Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente and University of Twente, Enschede, The Netherlands
    Arthritis Res Ther 10:R144. 2008
    ..We estimated the cost effectiveness of concomitant proton pump inhibitors (PPIs) in relation to the occurrence of non-steroidal anti-inflammatory drug (NSAID) ulcer complications...
  10. ncbi request reprint Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Transfus Med 15:379-87. 2005
    ..Validation of several crucial parameters is required, in particular the Dutch risk for acquiring and dying of transfusion-related sepsis...
  11. ncbi request reprint Further evidence for favorable cost-effectiveness of elderly influenza vaccination
    Maarten J Postma
    University of Groningen, Groningen University Institute for Drug Exploration GUIDE, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 6:215-27. 2006
    ..From the vast majority of studies it appears that financial benefits of elderly influenza vaccination surpass the costs and that, when this is not the case, cost-effectiveness in terms of net costs per life-year gained is acceptable...
  12. ncbi request reprint Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute for Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Vaccine 23:5365-71. 2005
    ..To assess the economic implications of strategies for influenza control among healthy working adults in The Netherlands...
  13. doi request reprint Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, The Netherlands
    Expert Rev Anti Infect Ther 8:1431-9. 2010
    ..This article builds on a roundtable meeting of the Pandemic Influenza Economic Impact Group that was held in Boston, MA, USA, in December 2008...
  14. doi request reprint International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference
    Maarten J Postma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 9:305-7. 2009
    ....
  15. ncbi request reprint Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance
    M J Postma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Sex Transm Infect 84:152-4. 2008
    ....
  16. ncbi request reprint Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands
    Maarten J Postma
    Graduate Schools SHARE and GUIDE, Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 25:497-509. 2007
    ..Oseltamivir is effective in the treatment of influenza. Utilisation in The Netherlands is limited, but increasing...
  17. doi request reprint Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands
    Cornelis Boersma
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:1103-21. 2010
    ..Albuminuria is a marker for renal and cardiovascular (CV) risk, allowing early diagnosis of subjects with elevated renal and CV risk...
  18. ncbi request reprint Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen UniversityInstitute for Drug Exploration, Groningen, The Netherlands
    Clin Ther 28:432-44. 2006
    ....
  19. doi request reprint Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006
    Hong Anh T Tu
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:133-44. 2010
    ..In addition, the duration of use and the costs of these treatments were investigated...
  20. doi request reprint Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data
    Cornelis Boersma
    Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics PE2, University of Groningen, Groningen, The Netherlands
    Am J Cardiovasc Drugs 10:49-54. 2010
    ....
  21. doi request reprint Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
    Marinus van Hulst
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Transfusion 49:2729-42. 2009
    ..This study attempted to accomplish this by providing an easy-to-use Web interface at http://www.bloodsafety.info that allows decision makers to adapt this model to local conditions...
  22. ncbi request reprint Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data
    Robin de Vries
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy, Groningen, The Netherlands
    Value Health 9:1-11. 2006
    ..To estimate the cost-effectiveness of a systematic one-off Chlamydia trachomatis (CT) screening program including partner treatment for Dutch young adults...
  23. doi request reprint Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, Netherlands
    BMJ 340:c2509. 2010
    ....
  24. doi request reprint Cost-utility of repeated screening for Chlamydia trachomatis
    Robin de Vries
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy, Groningen, The Netherlands
    Value Health 11:272-4. 2008
    ..To estimate the cost-effectiveness of repeated screening for chlamydia trachomatis at various time intervals compared to one-off screening of Dutch young adults...
  25. pmc Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events
    Cornelis Boersma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Br J Clin Pharmacol 65:723-32. 2008
    ..It could therefore be expected that especially subjects with higher albuminuria levels may benefit from blood pressure-lowering agents to improve their cardiovascular outcome...
  26. doi request reprint Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health
    Robin de Vries
    Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 27:846-52. 2009
    ..Furthermore, we showed the large impact of the discount rate for health on the cost-effectiveness of a HP vaccination program, illustrative for other vaccination programs...
  27. doi request reprint Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 11:1415-28. 2012
    ..In future, dynamic transmission models for pertussis should be used widely to further enhance understanding of pertussis epidemiology and of extended pertussis vaccination programs that are currently considered in various countries...
  28. ncbi request reprint Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands
    Cornelis Boersma
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University for Drug Exploration GUIDE, Groningen, The Netherlands
    Appl Health Econ Health Policy 4:191-6. 2005
    ..However, drug costs may not decrease after patent expiry, because of a lack of price competition and different national pricing systems...
  29. doi request reprint Economic evaluations of rotavirus immunization for developing countries: a review of the literature
    Hong Anh T Tu
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 10:1037-51. 2011
    ....
  30. ncbi request reprint Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making
    Cornelis Boersma
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, Groningen, The Netherlands
    Pharmacoeconomics 24:523-35. 2006
    ..This will result in a proper pharmacoeconomic outcome, where both types of drugs can be compared for healthcare decisions...
  31. ncbi request reprint Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands
    Jasper M Bos
    Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Pharmacoeconomics 24:141-53. 2006
    ....
  32. doi request reprint Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands
    Mark H Rozenbaum
    Department of Pharmacy, University of Groningen, The Netherlands
    Clin Ther 32:1517-32. 2010
    ..Community-acquired pneumonia and invasive pneumococcal disease are common among older people (ie, those aged > or =65 years). A new 13-valent pneumococcal conjugate vaccine (PCV-13) is under study in the Netherlands...
  33. doi request reprint On discounting of health gains from human papillomavirus vaccination: effects of different approaches
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Value Health 15:562-7. 2012
    ..Different approaches to discount health effects have been proposed. In this study, we estimated the impact of different approaches for discounting health benefits of human papillomavirus (HPV) vaccination...
  34. doi request reprint Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries
    Hong Anh T Tu
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 30:1521-8. 2012
    ....
  35. ncbi request reprint Compliance, persistence, and switching patterns for ACE inhibitors and ARBs
    Stefan Vegter
    Unit of Pharmaco Epidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Am J Manag Care 17:609-16. 2011
    ..To investigate compliance, persistence, and switching patterns for angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)...
  36. ncbi request reprint An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands
    Cornelis Boersma
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Clin Ther 29:963-71. 2007
    ..Compared with atenolol, losartan reduced the combined risk for CVD-related morbidity and mortality by 13% (P = 0.021), and reduced the risk for stroke by 25% (P = 0.001), with comparable blood pressure control in both trial arms...
  37. doi request reprint Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence
    Petros Pechlivanoglou
    Department of Pharmacoepidemiology and Pharmacoeconomics PE2, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 29:737-51. 2011
    ..Furthermore, we show that the results of cost-effectiveness analyses are highly dependent on several crucial factors that influence the baseline IFI incidence rates and, therefore, differ per patient population or region...
  38. doi request reprint Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism
    Stefan Vegter
    Departments of Pharmacy, University Medical Centre Groningen, Groningen, The Netherlands
    Pharmacogenet Genomics 19:695-703. 2009
    ..Furthermore, we considered a selective screen-and-treat strategy in which patients are prescribed alternative, more effective, therapy based on their ACE (I/D) polymorphism...
  39. ncbi request reprint Adherence of pharmacoeconomic studies to national guidelines in the Netherlands
    Jarir Atthobari
    Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, A Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Pharm World Sci 27:364-70. 2005
    ..All Dutch pharmacoeconomic studies that were published in English during 2000-2002 were selected for our review. Two reviewers examined each study for relevance and compared each study with the nine methodological guidelines selected...
  40. doi request reprint Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first-time and repeat blood donations in Zimbabwe: implications on blood safety
    Tonderai Mapako
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, Netherlands Planning, Information and Research Department, Coordination Department, Medical Services Department, National Blood Service Zimbabwe Department of Community Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe Department of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, Netherlands
    Transfusion 53:2413-21. 2013
    ..To evaluate the impact of discarding first-time donations on blood safety the HIV prevalence, incidence, and residual risk in first-time and repeat donations (wet packs) were compared...
  41. pmc Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents
    Giedre Gefenaite
    Department of Pharmacy, PharmacoEpidemiology and PharmacoEconomics PE2, University of Groningen, Groningen, The Netherlands
    BMC Public Health 12:498. 2012
    ..The Dutch Human Papillomavirus (HPV) catch-up vaccination program in 2009 appeared less successful than expected. We aimed to identify the most important determinants of refusing the vaccination...
  42. doi request reprint Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands
    Pieter T de Boer
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Netherlands
    Vaccine 31:1276-83. 2013
    ..A large randomized clinical trial, labelled the Shingles Prevention study (SPS), demonstrated that a live attenuated VZV vaccine can reduce the incidence of HZ and PHN...
  43. ncbi request reprint [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses]
    Tjalke A Westra
    Universitair Medisch Centrum Groningen, Afd Medische Microbiologie, sectie Moleculaire Virologie, Groningen, The Netherlands
    Ned Tijdschr Geneeskd 153:A356. 2009
    ..The actual health benefits gained by HPV vaccination are strongly dependent on vaccination coverage. It is therefore important that this remains high (85-100%)...
  44. ncbi request reprint Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting
    Rogier M Klok
    Groningen University Institute for Drug Exploration, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, The Netherlands
    Clin Ther 27:1647-57. 2005
    ..We performed an economic analysis of a Helicobacter pylori test-and-treat strategy versus a prompt endoscopy approach in a primary care setting...
  45. doi request reprint Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands
    Tjalke A Westra
    Department of Pharmacy, University of Groningen, The Netherlands
    Clin Ther 32:1479-95. 2010
    ..Because pertussis is most severe in unimmunized infants and infants who have only received some of the recommended doses, new pertussis immunization strategies should be considered to protect this vulnerable population...
  46. doi request reprint Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 10:187-99. 2011
    ..We conclude that the health and economic impact should be addressed in light of the country specific pneumoccocal disease epidemiology to support decisions on immunization programs...
  47. ncbi request reprint Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Expert Rev Vaccines 2:477-82. 2003
    ....
  48. pmc Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands
    Hiltsje Hepkema
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    PLoS ONE 8:e65036. 2013
    ..Despite its success, herd immunity may wane over time. Recently, a serogroup A,C,W135,Y meningococcal conjugate vaccine (MenACWY) was licensed for use in subjects of 12 months of age and above...
  49. ncbi request reprint A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention
    Jelena Stevanovic
    Department of Pharmacoepidemiology and Pharmacoeconomics PE2, University of Groningen, Antonius Deusinglaan 1, Groningen, The Netherlands
    Eur J Prev Cardiol 19:42-53. 2012
    ..In this article, we summarize the literature on the application of these risk models in pharmacoeconomic studies for primary cardiovascular disease prevention interventions in high-income countries...
  50. ncbi request reprint Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections
    Robin de Vries
    Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 26:75-90. 2008
    ..As the diagnosis of invasive fungal infections is difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has been the most commonly used...
  51. doi request reprint Economic evaluation of folic acid food fortification in The Netherlands
    Janneke Jentink
    Graduate Schools SHARE and GUIDE, Department of Social Pharmacy and Pharmacoepidemiology, University of Groningen, Groningen, The Netherlands
    Eur J Public Health 18:270-4. 2008
    ..We designed our study to estimate cost-effectiveness of folic acid food fortification in the Netherlands...
  52. doi request reprint Cost-effectiveness of HIV screening of blood donations in Accra (Ghana)
    Marinus van Hulst
    Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
    Value Health 11:809-19. 2008
    ....
  53. ncbi request reprint Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands
    Adrianne Faber
    Groningen University Institute for Drug Exploration, University of Groningen, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands
    CNS Drugs 22:157-70. 2008
    ..Stimulants are the drugs of first choice in the treatment of ADHD. It has been suggested that full costs associated with the treatment of ADHD may be reduced by once-daily administration regimens of stimulants...
  54. doi request reprint Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar)
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 28:2367-9. 2010
    ....
  55. doi request reprint Health economics of blood transfusion safety--focus on sub-Saharan Africa
    Marinus van Hulst
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Biologicals 38:53-8. 2010
    ..This review discusses the health economic evaluations of strategies to enhance blood product safety in sub-Saharan Africa...
  56. ncbi request reprint Cost-effectiveness of widespread screening for Chlamydia trachomatis
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Expert Opin Pharmacother 3:1443-50. 2002
    ..Illustrations are drawn from recent work in The Netherlands, which may also be representative for other settings...
  57. ncbi request reprint Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Value Health 4:266-75. 2001
    ..To assess the cost-effectiveness of pharmacotherapy for male partners in screening women for asymptomatic infection with Chlamydia trachomatis (CT)...
  58. ncbi request reprint Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands
    Jasper M Bos
    Department of Social Pharmacy, Groningen University Institute for Drug Exploration Groningen Research Institute for Pharmacy, University Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Clin Ther 25:2614-30. 2003
    ..These diseases lead to substantial mortality, morbidity, and costs. The societal impact is especially severe because most cases occur in very young infants...
  59. ncbi request reprint Socio-economic aspects of extended STD screening in pregnancy
    M J Postma
    Groningen University for Drug Exploration GUIDE, Groningen, The Netherlands
    AIDS Care 12:731-5. 2000
    ..Further research should be directed to the economic aspects of paediatric HIV infection and the epidemiology of CT in pregnancy...
  60. ncbi request reprint Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Drugs 62:1013-24. 2002
    ..Pharmacoeconomics do, however, present only one argument for consideration aside from ethical issues, budgetary limits and psychosocial aspects...
  61. pmc Cancer incidence and mortality in Serbia 1999-2009
    Jovan Mihajlović
    Department of Pharmacoepidemiology and Pharmacoeconomics PE2, University of Groningen, Antonius Deusinglaan 1, 9713, AV Groningen, The Netherlands
    BMC Cancer 13:18. 2013
    ..These rates are additionally compared to European and global cancer epidemiology estimates. Finally, predictions on Serbian cancer incidence and mortality rates are provided...
  62. pmc Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713AV, Groningen, The Netherlands
    BMC Infect Dis 13:75. 2013
    ..In this study, we made an analytical comparison of the two vaccines in terms of cost-effectiveness including the additional benefits of cross-protection and protection against genital warts in comparison with a screening-only strategy...
  63. doi request reprint Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes
    Janneke Jentink
    University of Groningen, Groningen, The Netherlands
    J Med Econ 15:862-8. 2012
    ..In particular, to estimate the impact of teratogenicity on the costs per quality adjusted life year (QALY)...
  64. doi request reprint Cost-effectiveness of varicella vaccination programs: an update of the literature
    Mark H Rozenbaum
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Expert Rev Vaccines 7:753-82. 2008
    ..Despite that, those aspects limit the timeliness of our review and we believe that the current work does provide useful insights in the cost-effectiveness of varicella vaccination...
  65. doi request reprint A review of the literature on the economics of vaccination against TB
    Hong Anh T Tu
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 11:303-17. 2012
    ....
  66. pmc Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    BMC Med 9:84. 2011
    ....
  67. ncbi request reprint [Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance]
    Eelko Hak
    Rijksuniversiteit Groningen, Groningen Research Institute for Pharmacy GRIP, unit Farmaco epidemiologie and Farmaco economie FE2, Groningen, The Netherlands
    Ned Tijdschr Geneeskd 154:A1188. 2010
    ..To assess the annual productivity loss among hospital healthcare workers attributable to influenza and to estimate the costs and economic benefits of a vaccination programme from the perspective of the the employer...
  68. ncbi request reprint Discounting health effects in pharmacoeconomic evaluations: current controversies
    J M Bos
    Groningen, University Institute for Drug Exploration, Department of Social Pharmacy, Pharmacoepidemiology, Groningen, The Netherlands
    Pharmacoeconomics 23:639-49. 2005
    ..Instead, results should be presented in a non-aggregated manner that enables policy makers to value health gains according to timing and to which subpopulation they are accrued in...
  69. doi request reprint Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands
    Petros Pechlivanoglou
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:108-18. 2010
    ....
  70. ncbi request reprint Cost considerations in the treatment of colorectal cancer
    Frank G A Jansman
    Groningen University Institute for Drug Exploration, Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 25:537-62. 2007
    ....
  71. ncbi request reprint Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands
    G A A Hubben
    Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, University of Groningen, and Base Case, Healthcare Decision Support, Groningen, The Netherlands
    Vaccine 25:3669-78. 2007
    ....
  72. ncbi request reprint Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands
    M J Postma
    Groningen University Institute for Drug Exploration Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Pharmacoeconomics 19:215-22. 2001
    ..To assess the cost effectiveness (net costs per life year gained) of pneumococcal vaccination of elderly individuals aged 65 years and over in The Netherlands...
  73. ncbi request reprint Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery
    M van Hulst
    Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy Groningen University Institute for Drug Exploration Groningen Research Institute of Pharmacy GUIDE GRIP, The Netherlands
    Transfus Med 15:209-17. 2005
    ..Leucodepletion of erythrocytes is a cost-saving strategy in cardiac valve (+/-CABG) patients. However, probablistic analysis failed to show a significant difference with buffy-coat-depleted PC...
  74. ncbi request reprint Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands
    R M Klok
    Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration GUIDE, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Aliment Pharmacol Ther 23:1595-600. 2006
    ..To evaluate influences of patent expiry on therapeutic substitution, switch behaviour before and after patent expiry was investigated...
  75. doi request reprint Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis
    Folgerdiena M de Vries
    Unit of PharmacoEpidemiology PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Drugs 72:2365-73. 2012
    ..Individual trials have shown varying data on the efficacy of treatment with lipid-lowering statin therapy in the primary prevention of such events in diabetes...
  76. doi request reprint Cost-effectiveness of pertussis booster vaccination in the Netherlands
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 30:7327-31. 2012
    ..To conclude, we show that extended pertussis booster vaccination strategies are likely to be considered as cost-effective...
  77. pmc Analyzing generic and branded substitution patterns in the Netherlands using prescription data
    Petros Pechlivanoglou
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, A, Deusinglaan 1, 9713 AV Groningen, The Netherlands
    BMC Health Serv Res 11:89. 2011
    ..We aim to analyse the extent and nature of substitution in recent years and estimate the likelihood of generic or branded substitution in Dutch pharmacies in relation to various characteristics...
  78. pmc Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    BMC Public Health 11:462. 2011
    ..We aimed to investigate which factors had a major impact on cost-effectiveness and were primarily responsible for the large differences in previously estimated cost-effectiveness ratios...
  79. doi request reprint Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations
    Stefan Vegter
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:1651-61. 2010
    ....
  80. doi request reprint Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis
    Stefan Vegter
    Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, University of Groningen, Groningen, The Netherlands
    Value Health 14:852-8. 2011
    ..We determined the cost-effectiveness of the noncalcium-based phosphate binder lanthanum carbonate (LC) as second-line treatment of hyperphosphatemia after therapy failure with calcium-based binders (CB)...
  81. ncbi request reprint Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines
    Stefan Vegter
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 26:569-87. 2008
    ..For these goals, we provide a list of recommendations for good pharmacoeconomic practice deemed useful in the fields of pharmacogenetics and pharmacogenomics, regardless of country and origin of the economic analysis...
  82. ncbi request reprint Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases
    Jasper M Bos
    Groningen University Institute for Drug Exploration, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 22:1171-9. 2004
    ..A numerical example illustrates our approach. We discuss the associated potential implications for public health policy and discuss how the effects of the intervention can be additionally corrected for societal preferences...
  83. doi request reprint Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis
    Cornelis Boersma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Value Health 13:853-6. 2010
    ..Yet, since 2005, all new innovative do have to go through a cost-effectiveness evaluation though, with the assessment being focused on the methodology rather than on the exact cost-per-QALY outcome...
  84. doi request reprint Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes
    Maarten J Postma
    Department of Pharmacy, University of Groningen, Groningen, Netherlands
    J Med Econ 11:743-68. 2008
    ..How the findings of each of the studies considered related to the methods used for each analysis and the assumptions made were specifically reviewed...
  85. pmc Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model
    Robin de Vries
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    PLoS ONE 5:e13392. 2010
    ..Using this framework, we estimate the cost-effectiveness of universal adolescent pertussis booster vaccination at the age of 12 years in the Netherlands...
  86. doi request reprint Cost-effectiveness estimates for antenatal HIV testing in the Netherlands
    M H Rozenbaum
    Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Int J STD AIDS 19:668-75. 2008
    ..We show that universal HIV screening during pregnancy generates significant net cost savings and health benefits in most situations. Universal antenatal HIV screening is justified in Amsterdam from a health-economic point of view...
  87. doi request reprint Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening
    J A Land
    Department of Obstetrics and Gynaecology, University Medical Center Groningen, Groningen, The Netherlands
    Hum Reprod Update 16:189-204. 2010
    ..There is considerable debate over the exact complication rates after chlamydia infections, and more precise estimates of PID and tubal infertility are needed, for instance to be inserted in economic models...
  88. ncbi request reprint Pharmacoeconomic research
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands
    Pharm World Sci 25:245-6. 2003
    ..How should we interpret such pharmacoeconomic studies? To enhance accurate interpretation of such studies among our readership, we present the basic concepts of pharmacoeconomics in this commentary...
  89. doi request reprint Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms
    Mark P Connolly
    Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Groningen, The Netherlands
    Hum Fertil (Camb) 13:13-8. 2010
    ....
  90. ncbi request reprint Cost-effectiveness of leucocyte depletion of red-cell transfusions for patients undergoing cardiac surgery
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Vox Sang 84:65-7. 2003
  91. ncbi request reprint Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands)
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Groningen, The Netherlands
    Vaccine 22:1862-7. 2004
    ..Estimate cost-effectiveness of vaccination against hepatitis A virus (HAV) for children of ethnic minorities in Amsterdam...
  92. ncbi request reprint Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam
    J M Bos
    Groningen University for Drug Exploration/Groningen Research Institute for Pharmacy GUIDE/GRIP, Groningen, The Netherlands
    AIDS 15:2031-6. 2001
    ..CONCLUSION: Compared to other interventions in infectious diseases control in the Netherlands, screening of STD clinic attendees for HIV has an acceptable cost-effectiveness...
  93. ncbi request reprint [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis]
    M J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen
    Ned Tijdschr Geneeskd 146:855-9. 2002
    ..To assess the cost-effectiveness of vaccination to prevent invasive pneumococcal disease in the elderly...
  94. ncbi request reprint The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach
    J M Bos
    Graduate Schools SHARE and GUIDE, Groningen Research Institute of Pharmacy GRIP, University of Groningen, Groningen, The Netherlands
    Vaccine 25:6922-9. 2007
    ..However, if evidence on relevant RSV-related mortality would become available, higher pricing would be justified, while still remaining below accepted thresholds for cost-effectiveness...
  95. doi request reprint The long-term fiscal impact of funding cuts to Danish public fertility clinics
    Mark P Connolly
    Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Reprod Biomed Online 23:830-7. 2011
    ....
  96. doi request reprint Economic evaluations of hepatitis B vaccination for developing countries
    Hong Anh T Tu
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 8:907-20. 2009
    ....
  97. ncbi request reprint Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder
    Rogier M Klok
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Antonius Deusinglaan 1 9713 AV Groningen, The Netherlands
    Expert Rev Pharmacoecon Outcomes Res 7:459-67. 2007
    ..It must be considered whether the decreased likelihood of developing a severe side effect is worth the extra costs incurred with the combination of quetiapine/lithium...
  98. ncbi request reprint Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes
    Maarten J Postma
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy, The Netherlands
    Expert Opin Pharmacother 4:1543-50. 2003
    ..In particular, potential pharmacoeconomic implications and related methodological aspects of the recent RENAAL trial for losartan are considered...
  99. ncbi request reprint Pharmacoeconomics of gastrointestinal drug utilisation prior and post Helicobacter pylori eradication
    Rogier M Klok
    Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Department of Social Pharmacy, Pharmaco epidemiology and Pharmacotherapy, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Helicobacter 9:87-91. 2004
    ..We investigated this presumed positive monetary effect using General Practitioners prescribing data, including information in diagnosis...
  100. ncbi request reprint Pharmaco-economics of blood transfusion safety: review of the available evidence
    M van Hulst
    Department of Social Pharmacy, Groningen University Institute for Drug Exploration University of Groningen Research Institute of Pharmacy GUIDE GRIP, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Vox Sang 83:146-55. 2002
    ..This review discusses the pharmaco-economic evaluations of strategies to enhance blood product safety that have been published in the scientific literature...
  101. doi request reprint Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination
    M D M Assink
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 27:1119-26. 2009
    ..In particular, extension of influenza vaccination to groups of non-elderly adults and young children may lower excess prescriptions during these influenza periods for all three types of drug prescriptions investigated...